Cipla eyeing to scale up US core formulations sales

08 Aug 2022 Evaluate

Cipla is eyeing to scale up its US core formulations sales on the back of respiratory and peptide franchises while monitoring upcoming complex product launches in the second half of the current fiscal. Besides, the company is betting big on digitisation and emerging segments like biosimilars and mRNA aided medications to drive its next phase of growth.

The drug firm has embarked on the digital transformation of the value chain across functions, including finance, R&D, manufacturing, supply chain, HR, customer outreach and stakeholder engagement. Over the past few years, the company has set up several foundational elements to drive the digitisation and automation plans right from adopting latest trends to transform patient reach and customer care via digitalisation.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1327.00 14.15 (1.08%)
28-Jan-2026 15:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.85
Dr. Reddys Lab 1225.15
Cipla 1327.00
Zydus Lifesciences 895.65
Lupin 2133.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×